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Abstract- In acute lymphoblastic leukemia (ALL) patients treated with L-asparaginase, discontinuation of the 
drug occasionally occur due to severe drug complications or resistance, however, due to the high efficacy of 
this drug in the recovery of patients and the prevention of disease recurrence, resuming the drug regimen is 
preferred in most patients. What we did in this study was to evaluate and compare the effects of clinical 
outcomes in the two modes of continuing and discontinuing drug use. In this retrospective cohort study, all 
children with ALL who had been treated with L-asparaginase during the years 2005 to 2015 were included in 
the study and categorized into two groups receiving complete treatment regimen (n=160) and those who had to 
discontinue the drug due to appearing complications (n=9). The rate of relapse and mortality rate was 
determined and compared across the two groups with a median follow-up time of more than 5 years. 5-yrs 
Overall survival of all enrolled patients in the groups continued and discontinued was 91.4±2.5% and 
71.4±17.1%, respectively (P=0.792). Also, 5-yrs event-free survival of the two groups was 75.8±3.5% and 
71.4±17.1%, respectively (P=0.557. Relapse was revealed in 17.5% and 33.3% respectively and mortality in 
16.9% and 0.0% (P=0.261). However, the overall prevalence of hypersensitivity reaction to the drug was 
significantly higher in those patients who discontinued their drug regimen (100% versus 24.4%, P<0.001). 
Hypersensitivity reaction to drugs may be an important factor in discontinuing L-asparaginase in patients with 
ALL. The discontinuation of L-asparaginase supplementation due to various complications such as 
hypersensitivity reactions may be effective in the survival of these patients. However, accurate determination 
of the effect of discontinuation of this drug on the outcome of children with ALL requires a more comprehensive 
study with more complicated cases. 
© 2020 Tehran University of Medical Sciences. All rights reserved. 
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Acute lymphoblastic leukemia (ALL) is a 
hematological malignancy caused by uncontrolled 
production of leukocytes and is identified as the most 
common malignancy in children, accounting for 25-30% 
of all malignancies in this age group. Significant 
improvement has occurred in the treatment of ALL in 
recent years. The long-term survival rate of patients has 
been upgraded to 80% (1,2). Despite success in the 
treatment of ALL, over 20% of patients still have the 
failure to treat the disease. In addition, treated patients 
occasionally show high levels of treatment-induced 
toxicity that need to change the therapeutic strategy (3). 
Major drugs used in the phase of treatment include 
glucocorticoids, anthracyclines, vincristine, and L-
asparaginase, which are used for long-term treatment in 
these patients (4,5). Asparaginazes are enzymes derived 
from bacteria, and in this regard, three types of these 
enzymes are derived from E. Coli (6,7). In recent years, a 
significant improvement in ALL treatment has been 
obtained following the use of L-asparaginase and is 
therefore considered as the primary protocol for treating 
patients (8,9), however, determining severe side effects 
due to the toxicity of this drug is necessary for optimizing 
the dose of the drug and approaching the most appropriate 
therapeutic protocol. The use of a high dose of L-
asparaginase and long-term use of it to reduce relapses 
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and to achieve complete recovery of treatment is 
sometimes necessary (10). In addition, the combined 
formula of L-asparaginase with steroids and other 
chemotherapy drugs such as methotrexate, vincristine, 
and mercaptopurine can double the effectiveness of L-
asparaginase and bring about a better outcome for 
patients (11,12). Despite the successful role of L-
asparaginase in the treatment of ALL children, its use is 
limited in this age range due to complications as well as 
drug toxicity. 
Another important point when using L-asparaginase 
is the development of resistance patterns to L-
asparaginase, which is mainly the result of producing 
antibodies in response to this drug. Repeated 
administration of L-asparaginase doses has led to an 
increase in the production of various antibodies and, 
therefore, has resulted in more hypersensitivity reactions 
(13,14). Additionally, some patients have to discontinue 
drugs because of potential adverse drug reactions, and 
especially allergic reactions, which is another challenge 
in treating these patients. Since the ultimate objective of 
the various chemotherapy regimens is to increase the 
survival rate of these patients, the question of which 
medication discontinuation will affect the outcome of 
these patients is a subject that needs further studies. 
Therefore, we decided to study the outcome of 
discontinuation of L-asparaginase in children with ALL 
in the past 10 years. 
 
Materials and Methods 
 
In this retrospective cohort study, all children with 
ALL who had been treated with L-asparaginase during 
the years 2005 to 2015 were included in the study and 
categorized into two groups receiving complete treatment 
regimen (n=160) and those who had to discontinue the 
drug due to appearing complications (n=9). Since in each 
group, two bone marrow samples were taken 29 days after 
starting treatment as well as immediately after 
discontinuation of treatment, the success or treatment 
response or failure were also determined. Overall, 
patients were followed up routinely after discontinuation 
of treatment. During this period, the following patients 
were assessed for the probability of disease recurrence: 1) 
undergoing biopsy of the testes due to painless swelling 
of the testis, 2) palsy undergoing lumbar puncture 
referred with the symptoms of increased CSF pressure or 
cerebral, 3) undergoing bone marrow aspiration due to the 
appearance of fever, bone pain, bleeding, petechiae and 
purpura, lymphadenopathy, splenomegaly, or blast in 
peripheral blood. In the final, the rate of relapse and 
mortality rate were determined and compared across the 
two groups continued the treatment and those who 
discontinued the consumption of drugs.  
The results for the quantitative variables were 
expressed as mean and standard deviation (mean±SD) 
and as number (percentage) for the qualitative variables. 
The t-test or Mann-Whitney U test was used to compare 
the quantitative variables. The Chi-square test also made 
a comparison between qualitative variables. To determine 
the event-free and overall survival of the patients within 
5 years of follow-up, the Kaplan-Mayer analysis was 
employed. SPSS-23 software was used to analyze the 
data. The P of less than 0.05 was considered as 




Overall, 169 patients were initially assessed that 9 
(5.3%) had to discontinue the treatment protocol with L-
asparaginase. Compared the two groups with regard to 
baseline variables including gender, mean age, and 
laboratory baseline parameters (Table 1) showed that the 
patients discontinued the drug were older than other 
patients while gender distribution, mean hemoglobin 
level, the mean number of platelet and WBC counts were 
similar in the two groups. The median follows up of all 
enrolled patients in the two groups was 75.40 and 62.93 
months, respectively (P=0.985). Within this time, the rate 
of relapse was revealed in 17.5% and 33.3%, 
respectively, and mortality in 16.9% and 0.0% revealing 
a difference across the two groups in terms of treatment 
outcome, but they were not statistically significant 
(P=0.261). However, the overall prevalence of 
hypersensitivity reaction to the drug was significantly 
higher in those patients who discontinued their drug 
regimen (100% versus 24.4%, P<0.001). In the two 
groups with and without hypersensitivity reaction, 58.3% 
and 59.5% were males, respectively, with no difference 
(P=0.889). According to the survival analysis, the 5-yr 
overall survival (OS) of all enrolled patients was 
90.3±2.6% (Figure 1). The five-year OS in the groups 
continued and discontinued L-asparaginase regimen was 
also 91.4±2.5% and 71.4±17.1%, respectively (P=0.792, 
Table 2, and Figure 2). The 5-yr event-free survival (EFS) 
of all enrolled patients was 75.5±3.6% (Figure 3). The 
five-year EFS in the groups continued, and discontinued 
L-asparaginase regimen was 75.8±3.5% and 71.4±17.1%, 
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Table 1. Comparing baseline parameters in the two groups 
Parameter Continuing drug Discontinuing drug P 
Gender    0.999 
Male  95 (59.4) 5 (55.6)  
Female  65 (40.6) 4 (44.4)  
Mean age  5.49 ± 3.50 8.04 ± 4.82 0.040 
Mean hemoglobin 12.56 ± 4.39 9.43 ± 0.66 0.483 
Mean platelet count 86294.77 ± 7612.89 122111.11 ± 42318.71 0.428 
Mean WBC count  24764.15 ± 3275.18 22100.00 ± 11867.17 0.850 
Median follow-up time (mo) 75.40 62.93  
 
 
Figure 1. Overall survival of all enrolled patients 
 
 
Table 2. 5-year survival in the two groups 
Parameter Continuing drug Discontinuing drug P 
Free-even survival   0.557 
1- year 89.3% 100%  
2-year 86.7% 100%  
3-year 82.8 100%  
4-year 79.4 100%  
5-year 75.8 71.4%  
Overall survival   0.792 
1- year 98.7% 100%  
2-year 98.7% 100%  
3-year 97.2% 100%  
4-year 93.0% 100%  




Figure 2. Overall survival analysis of all enrolled patients with vs without asparginase usage 
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Figure 3. Event-free survival of all enrolled patients 
 
 





In ALL patients treated with L-asparaginase, 
discontinuation of the drug occasionally occurs due to 
severe drug complications or resistance, however, due to 
the high efficacy of this drug in the recovery of patients 
and the prevention of disease recurrence, resuming the 
drug regimen is preferred in most patients. What we did 
in this study was to evaluate and compare the effects of 
clinical outcomes in the two modes of continuing and 
discontinuing drug use. What was considered as a 
consequence of the evaluation was the examination of 
recovery, recurrence, or mortality during follow-up in 
patients. In this study, patients in both groups were 
followed up for more than 5 years. Finally, in addition to 
studying mortality, relapse, and drug hypersensitivity, 5-
year event-free survival and, as well as five-year overall, 
were compared between the two groups. 
In summary, we found the following points. First, 
there was no statistical difference between the two groups 
with the continuation and discontinuation of the drug in 
the rate of improvement, the frequency of relapses, and 
the frequency of mortality; this may be due to the reduced 
number of cases in the second group. However, 
hypersensitivity reaction to drugs was significantly 
higher in the group with discontinuation of the 
medication. Secondly, there was no difference between 
the two groups in evaluating the five-year survival of 
patients. As previously mentioned, although the use of 
high-dose and long-term use of L-asparaginase in 
necessary to reduce relapses and to achieve complete 
recovery of the treatment, its use at a young age is limited, 
and due to its complications, including drug toxicity, it is 
restricted. In particular, hypersensitivity reactions are one 
of the most common side effects of this drug as a major 
cause of drug discontinuation. In the present study, 
hypersensitivity reactions have been reported as an 
essential factor in the discontinuation of drug use. But 
more importantly, the continuation or discontinuation of 
L-Asparaginase similarly affects the long-term survival 
of patients. In other words, the pursuit of treatment 
regimens with and without continued administration of 
the drug leads to a long-term favorable outcome in 
patients. Of course, in our study, the number of patients 
in the drug discontinuation group was significantly lower, 
and this issue was considered as a limitation of the study. 
Therefore, the actual effect of L-asparaginase 
continuation on the long-term outcome of patients should 
be tested in later studies with a higher power. 
In summary, what should be considered in this study 
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is firstly the introduction of hypersensitivity reactions as 
one of the most important factors in discontinuing the use 
of L-asparaginase in patients with ALL. As a second 
point, the discontinuation of L-asparaginase due to such 
a complication has not had a significant effect on the 
long-term survival of patients, probably because in both 
groups, it was a balance between the therapeutic efficacy 
of the drug and its complications. In a study by Usami et 
al., first, the mean five-year event-free survival and 
overall survival of patients were estimated to be 94.4% 
and 97.5%, respectively, which was very close to the 
values obtained. But in their study, discontinuation of L-
asparaginase drug was a predictor of poor prognosis and 
low survival (15). Of course, their study was first done on 
larger sample size, and secondly, a study was conducted 
on the Southeast Asian race, which could indicate a 
significant racial and genetic effect on the efficacy of the 
drug on the prognosis of patients, which, of course, needs 
to be studied more widely. In another study by Yen et al., 
of the 700 patients enrolled in the study, 33 discontinued 
L-asparaginase treatment. The 5-year survival of patients 
with and without drug discontinuation did not differ (81% 
versus 88%) (16), which was consistent with our study. 
Also, in the study of Larson et al., the three-year survival 
of patients receiving 14, 12 to 13, and lower than 11 doses 
of L-asparaginase were 55, 47, and 48 percent, 
respectively, with no significant difference (17), 
therefore, the outcomes of the disease were not dependent 
on the prescribed dosage of the drug, which could be 
consistent with our study. 
Hypersensitivity reaction to drugs may be an 
important factor in discontinuing L-asparaginase in 
patients with ALL. The discontinuation of L-asparaginase 
supplementation due to various complications such as 
hypersensitivity reactions may be effective in the survival 
of these patients. However, accurate determination of the 
effect of discontinuation of this drug on the outcome of 
children with ALL requires a more comprehensive study 
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